Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy, Safety, and Tolerability of Ezetimibe in Coadministration With Simvastatin in the Therapy of Adolescents With Heterozygous Familial Hypercholesterolemia

Trial Profile

Efficacy, Safety, and Tolerability of Ezetimibe in Coadministration With Simvastatin in the Therapy of Adolescents With Heterozygous Familial Hypercholesterolemia

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jul 2014

At a glance

  • Drugs Ezetimibe (Primary) ; Simvastatin
  • Indications Hypercholesterolaemia; Hyperlipoproteinaemia type II
  • Focus Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough; Schering-Plough Research Institute
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 04 Nov 2009 Schering-Plough has been merged into Merck & Co under the name Merck & Co., according to Merck & Co media release.
    • 21 Oct 2008 Primary endpoint 'Low density lipoprotein cholesterol level' has been met according to results published in the Journal of the American College of Cardiology .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top